Last reviewed · How we verify
Clarithromycin-Amoxicillin
Clarithromycin-Amoxicillin, marketed by Buddhist Tzu Chi General Hospital, is a combination therapy with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and dual-action mechanism. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Clarithromycin-Amoxicillin |
|---|---|
| Also known as | Clarithromycin(Klaricid), Amoxicillin(Hiconcil) and, Rabeprazole(Pariet) for 7 days. |
| Sponsor | Buddhist Tzu Chi General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clarithromycin-Amoxicillin CI brief — competitive landscape report
- Clarithromycin-Amoxicillin updates RSS · CI watch RSS
- Buddhist Tzu Chi General Hospital portfolio CI